<div id="readability-page-1"><p>Dana Investment Advisors Inc. lessened its holdings in shares of  Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 46.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 48,278 shares of the biopharmaceutical company's stock after selling 42,334 shares during the period. Dana Investment Advisors Inc.'s holdings in Bristol Myers Squibb were worth $2,604,000 as of its most recent filing with the SEC.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li></ul><p>A number of other institutional investors also recently modified their holdings of BMY. Vanguard Group Inc. raised its holdings in shares of  Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the last quarter.  State Street Corp raised its holdings in shares of  Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter.  Dimensional Fund Advisors LP raised its holdings in shares of  Bristol Myers Squibb by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after purchasing an additional 1,873,618 shares during the last quarter.  Legal &amp; General Group Plc increased its holdings in  Bristol Myers Squibb by 8.4% during the third quarter. Legal &amp; General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock worth $770,116,000 after buying an additional 1,317,199 shares during the last quarter.  Finally, Pzena Investment Management LLC boosted its stake in  Bristol Myers Squibb by 0.4% in the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock valued at $672,062,000 after acquiring an additional 58,129 shares during the last quarter. 76.41% of the stock is owned by institutional investors. </p><h2>Key Bristol Myers Squibb News</h2><p>Here are the key news stories impacting Bristol Myers Squibb this week:</p><ul>   <li><span>Positive Sentiment: </span>Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. <i></i><span>Bristol-Myers Strikes $15.2 Billion China Drug Deal</span></li>   <li><span>Positive Sentiment: </span>Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. <i></i><span>MarketBeat Bristol Myers Squibb estimates update</span></li>   <li><span>Positive Sentiment: </span>Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. <i></i><span>Tempus expands strategic collaboration with Bristol Myers Squibb</span></li>   <li><span>Positive Sentiment: </span>Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. <i></i><span>Tigerlily Foundation collaborates with Bristol Myers Squibb</span></li>   <li><span>Neutral Sentiment: </span>Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. <i></i><span>Bristol-Myers Squibb Company presents at conference transcript</span></li>   <li><span>Neutral Sentiment: </span>Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. <i></i><span>Bristol-Myers Squibb buy sell or hold post Q1 earnings</span></li>   <li><span>Negative Sentiment: </span>One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. <i></i><span>Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback</span></li> </ul><h2>Insider Activity</h2><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>In other news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders own  0.05% of the company's stock. </p><h2>Bristol Myers Squibb Trading Up 0.1%</h2><p>Shares of Bristol Myers Squibb stock opened at $57.04 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a market cap of $116.48 billion, a PE ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a 50 day simple moving average of $58.63 and a two-hundred day simple moving average of $55.43. </p><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb's revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.  Analysts expect that  Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year. </p><h2>Bristol Myers Squibb Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb's payout ratio is 70.79%. </p><h2>Analyst Ratings Changes</h2><p>BMY has been the subject of a number of research reports. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, April 8th. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a &#34;hold&#34; rating in a research note on Tuesday, March 17th. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. Finally, Guggenheim  restated a &#34;buy&#34; rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $61.31.</p><p><b>Read Our Latest Report on BMY</b></p><h2>Bristol Myers Squibb Company Profile</h2> (Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li><li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li><li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li><li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li></ul><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.</p>

Market Beat

Bristol Myers Squibb

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

iShares US Pharma

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Direxion Pharma & Medical Bull 3X

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Nasdaq Biotechnology ETF

ProShares Ultra Health Care ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

State Street

Legal & General Group Plc

Hengrui Pharma

Bank of America

Bristol-Myers Squibb Company

State Street® US Equity Premium Inc ETF

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY